In its recent guidance “Evaluation of Bulk Drug Substances Nominated for Use in Compounding” for outsourcing facilities, FDA again prioritized the use of FDA-approved drugs over more risky, custom-made medicines produced in bulk.

The guidance limits the raw substances that outsourcing facilities can use to make medicines in bulk that do not go through